The FDA has approved Rybrevant Faspro (amivantamab with hyaluronidase) as a subcutaneous injection for adults with EGFR-mutated non-small cell lung cancer, covering all previous intravenous indications.
The subcutaneous version works as well as the IV form, with similar effectiveness and overall survival, but can be given in about 5 minutes instead of 2–5 hours. It also greatly reduces infusion-related reactions, from 66% with IV to 13% with SC.
Side effects are similar to the IV version, including rash, nail changes, fatigue, and nausea, with additional warnings for lung disease, blood clots, and embryo-fetal toxicity. This faster, easier delivery reduces treatment time and eases the burden on patients and healthcare facilities.